ReviewJournal of the American Society of Nephrology : JASN2026
Fifty Shades of Risk: Population Studies and the Genetic Architecture of Kidney Diseases.
Review in Journal of the American Society of Nephrology : JASN, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Determining Causality in Gene Discovery: A Nephrologist's Perspective with Insights from ATP6V0A4.Journal of the American Society of Nephrology : JASN · 2026Article
- Improving precision diagnosis in unexplained CKD.Clinical kidney journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Genetics is transforming medicine, providing the possibility of highly specific diagnoses, which in turn allow molecularly defined cohort studies that facilitate detailed insights into gene-specific or even variant-specific prognosis and treatments. Yet, our understanding of genetic variation is changing. Previously, genetic testing typically resulted in a binary result, where an underlying genetic cause was either identified or not. With the increasing availability of population genomic data, a more nuanced view is emerging. Many disease-associated variants can also be identified in the unaffected population, and the degree of enrichment in affected persons informs on the variant-associated risk. Whereas some variants have virtually complete penetrance, conforming to the old binary paradigm, others are just mildly enriched and thus may explain only part of the etiology. Moreover, the traditional paradigm of rare variants causing rare diseases, while common variants affect common disorders is changing as we recognize that rare variants constitute most of the overall genetic variation and thus contribute a much higher proportion of the heritability of common disorders than previously thought. Conversely, examples are emerging of common variants that contribute to rare recessive disorders. These insights from population genetics not only inform variant interpretation but also affect genetic counseling, especially if testing was conducted in a clinically unaffected individual, for instance in the context of cascade screening in the family of an affected relative. Depending on the variant-specific associated disease risk, a genetic testing result may not allow a clear distinction between affected and unaffected but only a prediction of the risk for developing the associated disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.